Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms
Pharmaceutical Investing Scilex Announces Pricing and Availability of ZTlido for the Commercial Launch of its First Product in October of 2018
Pharmaceutical Investing Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing
Pharmaceutical Investing 1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
Pharmaceutical Investing Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
Pharmaceutical Investing Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma
Pharmaceutical Investing Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido
Sorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1
Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast Facility
RUA GOLD Expands High-Grade Intercepts at Depth at Auld Creek: 5.9g/t AuEq over 9m and 48.3g/t AuEq over 1.25m
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
